Business
Gelesis to Present at Endocrine Society Annual Mtg
Gelesis to Present at Endocrine Society Annual Mtg.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \nRNS Number : 5160T PureTech Health PLC 21 March 2019 \n\n21 March 2019\nPureTech Health plc\n \nPureTech's Affiliate Gelesis Announces Three Presentations at Endocrine Society Annual Meeting\n \nPureTech Health plc (LSE: PRTC) (\"PureTech Health\"), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis, today announced that its affiliate Gelesis will deliver three poster presentations around its proprietary hydrogel platform at the Endocrine Society Annual Meeting (ENDO) in New Orleans from 23-26 March. \n \nEric Elenko, PhD, chief innovation officer at PureTech Health, said: \"We're proud of Gelesis' strong presence at The Endocrine Society Annual Meeting, one of the premiere forums for scientific exchange around obesity and metabolic disorders. These three posters provide additional support for the therapeutic potential of the Gelesis platform across a range of conditions.\"\n \nThe full text announcement from Gelesis is as follows:\nGelesis Announces Three Presentations at Annual Endocrine Society Meeting\nBOSTON, March 21, 2019 - Gelesis, a biotechnology company developing first-in-class mechanotherapeutics to treat obesity and other chronic diseases related to the gastrointestinal (GI) tract, today announced the Company will deliver three poster presentations at ENDO, the Endocrine Society Annual Meeting, held in New Orleans from March 23-26. \nTwo of the presentations will share expanded clinical data from the pivotal study of Gelesis100, an oral, non-systemic approach to weight loss. A third will highlight preclinical data suggesting a different product candidate derived from Gelesis' proprietary hydrogel platform can restore gut barrier function in mice with severe gut wall injury. \n\"We are pleased to share expanded clinical data which seeks to address crucial public health issues associated with overweight and obesity. We are also excited to present our latest research on leveraging our hydrogel technology in chronic diseases of the GI system,\" said Harry L. Leider, MD, MBA, FACPE, Chief Medical Officer of Gelesis. \"We look forward to discussing our findings with the scientific community.\"\nDetails of the presentations are as follows:\nPoster Title: Gelesis100 Reduces Insulin Resistance in Patients Who Are Overweight or Ha...